📰 Gregory Riely News
Gregory Riely News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Gregory Riely. Real-time updates on events, politics, business and more.
October 12, 2023
Pfizer Inc. said Thursday the U.S. Food and Drug Administration has approved its Braftovi plus Mektovi combination therapy as a treatment for patients with...
October 12, 2023
Encorafenib (Braftovi; Pfizer Inc) and binimetinib (Mektovi; Pfizer Inc) approved for the treatment of patients with metastatic non-small cell lung cancer who harbor a BRAF V600E mutation.
October 12, 2023
Pfizer Inc (NYSE:PFE) announced that the United States Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) plus MEKTOVI (binimetinib) for...
October 12, 2023
Encorafenib plus binimetinib led to 75% ORR in untreated patients, 59% in treated patients
October 12, 2023
The combination of Braftovi (encorafenib) plus Mektovi (binimetinib) is approved for metastatic NSCLC with a BRAF V600E mutation.
October 12, 2023
The single-arm approval study reported an objective response rate of 75% among treatment-naive patients.
October 5, 2022
The new PD-1 inhibitor from China yielded positive results in a phase 3 trial, and a further trial in the US is now planned to bolster prospects for FDA approval.